UBS AM
BIO icon

UBS AM’s Bio-Rad Laboratories Class A BIO Stock Holding History

UBS AM’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123M Sell
418,884
-7,154
-2% -$2.03M 0.02% 478
2026
Q1 		$119M Buy
426,038
+30,961
+8% +$8.92M 0.02% 477
2025
Q4 		$120M Sell
395,077
-2,094
-0.5% -$653K 0.03% 454
2025
Q3 		$111M Buy
397,171
+380,422
+2,271% +$104M 0.02% 455
2025
Q2 		$4.04M Sell
16,749
-366,058
-96% -$86.5M ﹤0.01% 1810
2025
Q1 		$93.2M Sell
382,807
-5,820
-1% -$1.75M 0.02% 558
2024
Q4 		$128M Sell
388,627
-52,471
-12% -$17.8M 0.03% 466
2024
Q3 		$148M Buy
441,098
+4,260
+1% +$1.35M 0.04% 418
2024
Q2 		$119M Buy
436,838
+14,681
+3% +$4.27M 0.03% 418
2024
Q1 		$146M Sell
422,157
-81,051
-16% -$26.7M 0.05% 348
2023
Q4 		$162M Sell
503,208
-71,322
-12% -$22.4M 0.06% 310
2023
Q3 		$206M Buy
574,530
+40,239
+8% +$15.5M 0.09% 228
2023
Q2 		$256M Hold
534,291
– – 0.12% 175
2023
Q1 		$256M Buy
534,291
+114,866
+27% +$53.8M 0.12% 175
2022
Q4 		$176M Buy
419,425
+25,392
+6% +$10.2M 0.09% 245
2022
Q3 		$164M Buy
394,033
+19,245
+5% +$9.59M 0.09% 240
2022
Q2 		$186M Buy
374,788
+28,416
+8% +$14.8M 0.1% 224
2022
Q1 		$195M Buy
346,372
+2,495
+0.7% +$1.5M 0.08% 259
2021
Q4 		$260M Sell
343,877
-13,723
-4% -$10.3M 0.1% 217
2021
Q3 		$267M Sell
357,600
-12,576
-3% -$9.42M 0.11% 191
2021
Q2 		$239M Sell
370,176
-12,624
-3% -$7.68M 0.1% 214
2021
Q1 		$219M Sell
382,800
-120,757
-24% -$71.5M 0.1% 223
2020
Q4 		$294M Buy
503,557
+117,413
+30% +$66.9M 0.14% 146
2020
Q3 		$199M Sell
386,144
-26,428
-6% -$13.4M 0.11% 176
2020
Q2 		$186M Buy
412,572
+46,288
+13% +$20.4M 0.11% 177
2020
Q1 		$128M Sell
366,284
-75,058
-17% -$27.6M 0.09% 220
2019
Q4 		$163M Buy
441,342
+22,837
+5% +$8.05M 0.1% 219
2019
Q3 		$139M Buy
418,505
+21,281
+5% +$6.94M 0.09% 228
2019
Q2 		$124M Buy
397,224
+10,536
+3% +$3.15M 0.09% 249
2019
Q1 		$118M Sell
386,688
-28,125
-7% -$7.59M 0.09% 249
2018
Q4 		$96.3M Buy
414,813
+160,075
+63% +$42.9M 0.08% 263
2018
Q3 		$79.7M Sell
254,738
-19,441
-7% -$6.03M 0.06% 335
2018
Q2 		$79.1M Sell
274,179
-6,296
-2% -$1.74M 0.06% 350
2018
Q1 		$70.1M Sell
280,475
-78,936
-22% -$20.1M 0.06% 372
2017
Q4 		$85.8M Sell
359,411
-51,887
-13% -$12.6M 0.07% 300
2017
Q3 		$91.4M Sell
411,298
-15,829
-4% -$3.56M 0.08% 266
2017
Q2 		$96.7M Sell
427,127
-9,706
-2% -$2.12M 0.09% 252
2017
Q1 		$87.1M Sell
436,833
-29,952
-6% -$5.77M 0.09% 254
2016
Q4 		$85.1M Buy
466,785
+38,714
+9% +$6.6M 0.1% 232
2016
Q3 		$70.1M Sell
428,071
-20,763
-5% -$3.15M 0.08% 281
2016
Q2 		$64.2M Buy
448,834
+33,077
+8% +$4.72M 0.07% 294
2016
Q1 		$56.8M Sell
415,757
-55,093
-12% -$7.23M 0.07% 322
2015
Q4 		$65.3M Sell
470,850
-105,749
-18% -$14.7M 0.07% 286
2015
Q3 		$77.4M Sell
576,599
-13,322
-2% -$1.92M 0.09% 266
2015
Q2 		$88.8M Buy
589,921
+36,118
+7% +$5.17M 0.09% 254
2015
Q1 		$74.9M Sell
553,803
-8,636
-2% -$1.07M 0.07% 295
2014
Q4 		$67.8M Sell
562,439
-6,156
-1% -$709K 0.06% 320
2014
Q3 		$64.5M Sell
568,595
-17,180
-3% -$2.04M 0.06% 324
2014
Q2 		$70.1M Sell
585,775
-12,096
-2% -$1.48M 0.07% 301
2014
Q1 		$76.6M Sell
597,871
-36,526
-6% -$4.68M 0.08% 274
2013
Q4 		$78.4M Buy
634,397
+69,735
+12% +$8.5M 0.09% 249
2013
Q3 		$66.4M Sell
564,662
-27,200
-5% -$3.21M 0.08% 272
2013
Q2 		$66.4M Buy
+591,862
New +$69.4M 0.09% 258

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM's BIO Position: Q2 2026 in Review

UBS AM reduced its Bio-Rad Laboratories Class A (BIO) stake by 1.7% in Q2 2026, selling an estimated $2.03M and leaving 418,884 shares worth $123M. The position accounts for 0.02% of the portfolio, ranked #478.

UBS AM first reported a position in BIO in Q2 2013 and has held it in 53 quarters since. The position peaked at $294M in Q4 2020. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • UBS AM held 418,884 shares of Bio-Rad Laboratories Class A worth $123M as of Q2 2026.
  • UBS AM sold 7,154 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $2.03M.
  • Bio-Rad Laboratories Class A made up 0.02% of UBS AM's portfolio in Q2 2026, its #478 holding.
  • UBS AM first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 53 quarters since.
  • UBS AM's Bio-Rad Laboratories Class A position peaked at $294M in Q4 2020.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.